Navigation Links
Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Date:12/3/2007

n decline in ALS-Functional Score was 5.27 in the celecoxib/creatine arm, compared to 6.47 in the minocycline/creatine arm, and 5.82 in the historical control group.

The trial's secondary objective was evaluation of futility, which showed that AL-08/celecoxib was non-futile compared to historical controls and the null hypothesis of at least a 25% reduction in the ALS-Functional Score could not be rejected. This combination was selected for a Phase III study.

ABOUT AVICENA

Avicena Group, Inc. (OTCBB:AVGO) is a Palo Alto, California based late- stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases. The Company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). Near term, the Company plans to initiate a confirmatory Phase III trial in ALS and a Phase III trial in Huntington's disease to accompany the ongoing NIH Phase III trial in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers.

SAFE HARBOR

This release contains forward-looking statements that reflect, among other things, management's current expectations, plans and strategies, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict. See "Risk Factors" under "Item 6. Management's Discussion and Analysis of Financial Condition and Results of Operation" from ou
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
2. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Biomedical Inc. ( www.synapsebiomedical.com ) announced today it ... of its NeuRx DPS® System for ALS patients.  ... enrollment requirement was implanted over a month and ... which is the only medical device approved by ... humanitarian device that obtained approval at the end ...
(Date:9/30/2014)... EXECUTIVE SUMMARY The present report ... - Increasing Demand from Ageing Population to Drive ... past, present and future outlook. The report discusses ... market with outlook to 2017. Statistics include functional ... sub-segments of the industry, ongoing trends and developments, ...
(Date:9/30/2014)... DURHAM, N.C. , Sept. 30, 2014 /PRNewswire/ ... that Viztek LLC (Viztek), a leading provider of ... licensed HeartIT,s zero footprint patent portfolio. The licensed ... to provide access to diagnostic-quality medical images in ... part of the agreement, Viztek and its Subsidiaries ...
Breaking Medicine Technology:Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 2North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 3
(Date:9/30/2014)... at the University of Michigan have described a new ... fraction of the time needed for more traditional methods. ... novel antibody that is undergoing further investigation as a ... , In research published online in the ... researchers in the lab of Stephen Weiss at the ...
(Date:9/30/2014)... Fla. (PRWEB) September 30, 2014 Lea ... is giving breast cancer patients a new, more practical ... , Women who undergo mastectomies, biopsies and lumpectomy surgeries ... promote healing. But after seeing her patients describe the ... compelled to create a new bra in her spare ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Brig Hart, ... history, who broke over 500 Diamond-ranked professionals using his ... doing it again. The Life Support System for ... he has been perfecting using his experiences and successes ... month. Using the principles and methodology taught by Brig ...
(Date:9/30/2014)... Farmington, NY (PRWEB) September 30, 2014 Timber ... design/build process for the Olsen family’s reclaimed Douglas fir ... will cover the home’s journey from architectural planning, to the ... Dee Olsen turned to New Energy Works, after following the ... to design and build their dream vacation home on land ...
(Date:9/30/2014)... September 30, 2014 ... , From:        Hope For The ... abarnwell(at)hopeforthewarriors(dot)org , Event:        Got ... , Date:        Thursday, October 2, ... and Navy Club, 901 ...
Breaking Medicine News(10 mins):Health News:New discovery approach accelerates identification of potential cancer treatments 2Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 2Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 3Health News:Brig Hart Announces the First Diamond Elite Representatives using his Life Support System 2Health News:Brig Hart Announces the First Diamond Elite Representatives using his Life Support System 3Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 2Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 3Health News:Hope For The Warriors' Got Heart, Give Hope Celebration Media Advisory 2
... , , ... US Oncology, Inc . today announced that US Oncology ... Phase III, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C), with or ... HER2-negative metastatic breast cancer. , , ...
... , , , , ... its online boutique, www.chemo-couture.com , featuring inspirational, handcrafted ... and loved ones. , , Inspired ... disease, Jane Bebita and Julie Uhrig joined forces to create an ...
... , , SEOUL, South Korea, July ... 039350) is pleased to announce that its wholly owned subsidiary, ... for the commercial, institutional, and consumer markets, has successfully turned the ... the world) green! Royal Laundry of South San Francisco ...
... , , , ... Resources, one of the world,s leading research and advisory firms focusing ... market in Brazil will grow from $200 million in 2008 to ... the tumor necrosis factor-alpha (TNF-alpha) inhibitors Abbott,s Humira and Schering-Plough,s Remicade ...
... , , BRIDGEWATER, N.J., ... that it is possible to recruit large numbers of women, ... The study, known as GRACE, is the largest study to ... and race differences in response to an HIV-1 therapy -- ...
... , WHITE PLAINS, N.Y. and CAMBRIDGE, Mass., July ... FORMA Therapeutics today announced a partnership to accelerate LLS,s pipeline of ... , The collaboration will begin with a selection of ... to have the most promise of advancing into clinical trials in ...
Cached Medicine News:Health News:US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201 2Health News:US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201 3Health News:US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201 4Health News:HepaHope Korea Subsidiary VASKA Introduces Green Chemicals to U.S. Commercial Laundry Industry 2Health News:Brazil's Rheumatoid Arthritis Drug Market Will Grow $115 Million by 2013 2Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 2Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 3Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 4Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 5Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 6Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 7Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 8Health News:The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 2Health News:The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 3
... The AngioJet Xpeedior+120 Rheolytic Thrombectomy catheter is ... performance. Powerful saline jets create a low ... a vacuum effect. Thrombus is drawn into ... the jets, and removed from the body.,AngioJet ...
... combined with a stimulation lead ... Temporary Pacemaker can be used ... pacing is indicated. The device ... as well as diagnostic purposes ...
... a unique left ventricular assist device that helps ... being used in a small group of patients ... of an FDA-approved Feasibility Study. The patient can ... power source for minutes or hours. The Kantrowitz ...
... new Bicycle Ergometer ... braking system which ... reliable service while ... The hyperbolic workload ...
Medicine Products: